Bone Marrow Transplant
Fludarabine + Radiation Followed by SCT for Ph+ ALL Patients (FHCRC-1581)
Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive PH+ Acute Leukemia - A Multi-Center Trial
Investigator: George Georges, MD; Conditions: Leukemia; Status: Recruiting; Study ID: NCT00036738
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Investigator: Dr. Gunnar Ragnarsson; Conditions: Leukemia , Myelodysplastic Syndromes (MDS); Status: Recruiting; Study ID: NCT00052520
Multi-center, Open label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, NK Cell Lymphoblastic Leukemia; Status: Recruiting; Study ID: NCT00429598
Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Investigator: Mohamed Sorror, MD, MSc; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00104858
A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects with Steroid-Refractory Chronic Graft-versus-Host Disease
Investigator: Stephanie Lee, MD, MPH; Conditions: Chronic Graft Versus Host Disease (cGVHD); Status: Recruiting; Study ID: NCT01226420
A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil
Investigator: David Maloney, MD, PhD; Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Recruiting; Study ID: NCT00089011
A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.
Investigator: Bart Scott, MD; Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Closed; Study ID: NCT00322101
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells for Patients with Malignant Gliomas
Investigator: Hans-Peter Kiem, MD; Conditions: Brain Cancer; Glioma; Solid Tumors; Status: Recruiting; Study ID: NCT00669669
A Multi-center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine
Investigator: Bill Bensinger, MD; Conditions: Hematologic Malignancies; Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT00217438
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor
Investigator: Leona Holmberg, MD, PhD; Conditions: Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01097057
Infusion of Off-the-Shelf Ex-Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients with Hematologic Malignancies
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Lymphoid Leukemia (ALL); Chronic Myeloid Leukemia (CML); Hematologic Malignancies; Leukemia; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD); Umbilical Cord Blood Transplant (UCBT); Status: Recruiting; Study ID: NCT01175785
HLA-Haploidentical Related Marrow Grafts for the Treatment of Immunodeficiency and Other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus.
Investigator: Lauri Burroughs, MD; Conditions: Immunodeficiency Syndromes, Severe Combined Immunodeficiency Syndrome (SCID); Status: Recruiting; Study ID: NCT00358657
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN 0801)
Investigator: Paul Carpenter, MD; Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Status: Recruiting; Study ID: NCT01106833
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia
Investigator: Joachim Deeg, MD; Conditions: Aplastic Anemia; Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Non-malignant Condition; Status: Recruiting; Study ID: NCT00326417
A Multicenter Phase I/II Study of the Prophylactic Inhibition of BCR-ABL Tyrosine Kinase by Tasigna ® (Nilotinib) after Hematopoietic Cell Transplantation for Philadelphia Chromosome-Positive Leukemias
Investigator: Paul Carpenter, MD; Conditions: Acute Lymphoid Leukemia (ALL); Chronic Myeloid Leukemia (CML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT00702403
Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial
Investigator: Brenda Sandmaier, MD; Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis; Status: Recruiting; Study ID: NCT00397813
High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-Infected Patients. BMT-CTN Protocol 0803 (AMC 071)
Investigator: Ann Woolfrey, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01141712
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Investigator: Bart Scott, MD; Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Status: Recruiting; Study ID: NCT01339910
Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
Investigator: Paul Martin, MD; Conditions: Bronchiolitis Obliterans, Chronic Graft-versus-host Disease; Status: Recruiting; Study ID: NCT00656058
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Investigator: Jason Chien, MD; Conditions: Chronic Graft Versus Host Disease (cGVHD); Status: Recruiting; Study ID: NCT01307462
A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics (PK)-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non-Hodgkin?s Lymphoma and Hodgkin?s Lymphoma
Investigator: Leona Holmberg, MD, PhD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT00948090
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia , Myelodysplastic Syndrome, Myeloproliferative Syndrome; Status: Recruiting; Study ID: NCT01300572
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Investigator: Steven Pergam, MD; Conditions: Herpes Zoster; Status: Recruiting; Study ID: NCT01229267
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Investigator: Ann Woolfrey, MD; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT01351545
A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis
Investigator: George Georges, MD; Conditions: Systemic Scleroderma; Status: Recruiting; Study ID: NCT01413100
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
Investigator: Marco Mielcarek, MD; Conditions: Chronic Graft Versus Host Disease (cGVHD); Status: Recruiting; Study ID: NCT01427881
A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients
Investigator: Stephanie Lee, MD, MPH; Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Status: Recruiting; Study ID: NCT01278927
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
Investigator: Paul Martin, MD; Conditions: Prevention of GvHD; Status: Recruiting; Study ID: NCT01379209
A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT01109004
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Investigator: Richard Nash, MD; Conditions: Autoimmune Diseases, Scleroderma, Systemic Sclerosis; Status: Recruiting; Study ID: NCT00622895
A Phase 1 Study of Nilotinib in Steroid Dependent / Refractory Chronic Graft Versus Host Disease
Investigator: Paul Carpenter, MD; Conditions: Chronic Graft Versus Host Disease (cGVHD); Status: Recruiting; Study ID: NCT01155817
Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study
Investigator: Hans-Peter Kiem, MD; Conditions: Fanconi Anemia, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT00453388
A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML
Investigator: Boglarka Gyurkocza, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01252667
Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma
Investigator: Marco Mielcarek, MD; Conditions: Graft Versus Host Disease, Multiple Myeloma , Plasma Cell Neoplasm and Plasma Cell Neoplasm; Status: Recruiting; Study ID: NCT00793572
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial
Investigator: David Maloney, MD, PhD; Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT00005803
Donor Lymphocyte Infusion for the Treatment Of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-Center Trial
Investigator: Brenda Sandmaier, MD; Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)Hodgkin's Lymphoma, Juvenile Myeloid Leukemia (JML), Leukemia, Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT00068718
A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate mofetil (MMF) for Prevention of Acute GVHD after Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation? A Multi-Center Trial
Investigator: Brenda Sandmaier, MD; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT01251575
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
Investigator: Brenda Sandmaier, MD; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT01231412
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin?s Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)
Investigator: Leona Holmberg, MD, PhD; Conditions: Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01100502
Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study
Investigator: Ann Woolfrey, MD; Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Status: Recruiting; Study ID: NCT00884572
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multicenter Trial
Investigator: Brenda Sandmaier, MD; Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphoid Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma (MM), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD), Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT00096161
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil
Investigator: Ann Woolfrey, MD; Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Immunodeficiency Syndromes; Malignancies in HIV Patients; Status: Recruiting; Study ID: NCT00112593
Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Relapsed or Refractory CD20+ B-Cell Malignancies
Investigator: Andrew Rezvani, MD; Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer; Status: Recruiting; Study ID: NCT00867529
Treatment of Post-Transplant Relapse and Persistent Disease in Patients with MDS, CMML and AML with Azacitidine +/- Gemtuzumab
Investigator: Bart Scott, MD; Conditions: Adult Acute Myeloid Leukemia (AML), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01083706
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Investigator: Mohamed Sorror, MD, MSc; Conditions: Chronic Lymphoid Leukemia (CLL) , Hematologic Malignancies, Hodgkin's Lymphoma, Leukemia , Lymphoma , Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01008462
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation
Investigator: Brenda Sandmaier, MD; Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Recruiting; Study ID: NCT00789776
A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors
Investigator: Ann Woolfrey, MD; Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Closed; Study ID: NCT00555048
A Pilot Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases
Investigator: Richard Nash, MD; Conditions: Nonneoplastic Condition; Status: Recruiting; Study ID: NCT00716066
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Investigator: Marie Bleakley, MD; Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD); Status: Recruiting; Study ID: NCT00914940
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Investigator: Boglarka Gyurkocza, MD; Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD); Status: Recruiting; Study ID: NCT00860574
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen
Investigator: Colleen Delaney, MD, MSc; Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Recruiting; Study ID: NCT00723099
Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant for Multiple Myeloma
Investigator: Leona Holmberg, MD, PhD; Conditions: Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT00839956
Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen
Investigator: Lauri Burroughs, MD; Conditions: Dyskeratosis Congenita, Graft Versus Host Disease, Nonneoplastic Condition, Shwachman-Diamond Syndrome; Status: Recruiting; Study ID: NCT00919503
A Randomized Multicenter Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies
Investigator: Stephanie Lee, MD, MPH; Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Status: Recruiting; Study ID: NCT00438958
A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors with an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies
Investigator: Colleen Delaney, MD, MSc; Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT00343798
A Randomized Phase 2 Study of Imatinib and Rituximab for Cutaneous Sclerosis in Patients with Chronic Graft-Versus-Host Disease
Investigator: Mary Flowers, MD; Conditions: Chronic Graft Versus Host Disease (cGVHD); Status: Recruiting; Study ID: NCT01309997
Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen
Investigator: Colleen Delaney, MD, MSc; Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT00719888
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen
Investigator: Colleen Delaney, MD, MSc; Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases; Status: Recruiting; Study ID: NCT00796068
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Investigator: Paul O'Donnell, MD, PhD; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT01028716
A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
Investigator: Richard Nash, MD; Conditions: Autoimmune Diseases; Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Scleroderma; Systemic Sclerosis; Non-malignant Condition; Status: Recruiting; Study ID: NCT00114530
Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®
Investigator: Lauri Burroughs, MD; Conditions: Immunodeficiency Syndromes, Severe Combined Immunodeficiency Syndrome (SCID); Status: Open; Study ID: NCT00553098
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Investigator: Pamela Becker, MD, PhD; Conditions: Fanconi Anemia Complementation Group A; Status: Recruiting; Study ID: NCT01331018
Join Us On